clinical trial · NCT04982848
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Pfizer·—·not yet recruiting·n = 600
Breast NeoplasmsTalzenna
brief summary
Talzenna will be approved for the treatment of gBRCA advanced breast cancer in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Talzenna after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Talzenna will be observed.
started
Jun 1, 2027
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Nov 18, 2025
official title
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Talzenna(Registered)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol